Migard (Frovatriptan)

Frovatriptan, the active ingredient in Migard, is a selective serotonin 5‑HT1B/1D receptor agonist presented as an oral tablet for oral use. It is indicated for the acute treatment of migraine attacks in adults.

GNH USA supplies Migard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Frovatriptan belongs to the triptan class and is used to treat migraine‑related conditions.

Migraine attack (with or without aura): provides rapid relief of headache pain and associated symptoms. Menstrual migraine: alleviates attacks that occur in relation to the menstrual cycle. Adult migraine (age ≥ 18): suitable for patients needing an oral triptan for acute episodes.

Frovatriptan may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Dizziness: transient light‑headedness. - Fatigue: feeling of tiredness. - Dry mouth: reduced salivation. - Chest discomfort: pressure or tightness in the chest. - Tingling: paresthesia in extremities.

Serious or Rare Side Effects: - Coronary vasospasm: reduced blood flow to the heart. - Severe hypertension: sudden high blood pressure. - Serotonin syndrome: potentially life‑threatening condition when combined with other serotonergic agents. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Myocardial infarction: rare heart attack occurrence.

Before prescribing Frovatriptan, clinicians should evaluate patient history and potential risks.

Assess cardiovascular risk: review history of coronary artery disease, angina, or stroke. Avoid in uncontrolled hypertension: ensure blood pressure is well‑controlled. Screen for drug interactions: check concurrent serotonergic medications. Use caution in patients over 65: monitor for increased sensitivity. Pregnancy and lactation: evaluate benefit‑risk ratio as safety data are limited. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Frovatriptan can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension and serotonin syndrome. - Other triptans or ergot alkaloids: additive vasoconstrictive effects. - SSRIs/SNRIs: increased potential for serotonin syndrome.

Moderate Interactions (Monitor Closely): - Antihypertensives: may enhance blood pressure‑lowering effects. - Oral contraceptives: possible alteration of efficacy. - CYP1A2 inhibitors (e.g., fluvoxamine): may increase Frovatriptan plasma levels.